- In October 2024, Valneva SE and LimmaTech Biologics announced that the FDA granted Fast Track designation to Shigella4V, the world’s most advanced tetravalent bioconjugate vaccine candidate for shigellosis, which Valneva licensed exclusively.
- In October 2023, Institut Pasteur announced a study of Phase 2 clinical trials for Injection SF2A-TT15 10 µg Adjuvanted. The aim of this research is to investigate the safety and effectiveness of a two-dose parenteral synthetic carbohydrate-based conjugate vaccine for Shigella flexneri 2a (SF2a-TT15) in infants in a Shigella-endemic country, Kenya. The study will explore the vaccine's immunogenicity and safety, comparing formulations with and without Alhydrogel as an adjuvant. The research adopts an age-descending approach, focusing on the vaccine's target population.
- In September 2023, International Centre for Diarrhoeal Disease Research, Bangladesh announced a study of Phase 2 clinical trials for Tebipenem Pivoxil, Azithromycin, and Ceftriaxon. The proposed study aims to investigate whether tebipenem-pivoxil is as effective as the currently WHO-recommended second-line therapy for Shigella (ceftriaxone).
- In June 2023, GlaxoSmithKline announced a study of Phase 1 & 2 clinical trials for altSonflex. The objective of this ongoing clinical trial is to assess, for the first time in humans, the safety and immune response elicited by the altSonflex1-2-3 candidate vaccine targeting S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The initial phase of the study involves administering the vaccine to adults aged 18 to 50 years in Europe.
Frequently Asked Questions
Africa is the fastest-growing region in the global shigellosis gastroenteritis treatment market, driven by a high burden of diarrheal diseases, increased public health interventions, and improving access to antibiotics and rehydration therapy.
A key trend in the global shigellosis gastroenteritis treatment market is the growing emphasis on antibiotic stewardship and the development of targeted therapies to combat drug-resistant Shigella strains.
The primary factor driving the market growth is the rising prevalence of shigellosis in developing regions, combined with improved diagnostic capabilities and increasing global efforts for infectious disease control.
Major challenges include increasing antibiotic resistance and limited access to clean water and sanitation in low-income countries, which continue to fuel transmission rates despite available treatments.
The ciprofloxacin segment is expected to dominate the global shigellosis gastroenteritis treatment market in 2025, accounting for the largest market share due to its effectiveness, widespread availability, and status as a first-line treatment in many clinical guidelines.
